Ann Bauer, a researcher who studies Tylenol and autism , felt queasy with anxiety in the weeks leading up to the White House's much-anticipated autism announcement .

In August, Bauer and her colleagues published an analysis of 46 previous studies on Tylenol, autism, and attention-deficit/hyperactivity disorder. Many found no link between the drug and the conditions, while some suggested Tylenol might occasionally exacerbate other potential causes of autism, such as genetics.

Bauer, an epidemiologist at the University of Massachusetts-Lowell, and her team called for more judicious use of the drug until the science is settled.

On Monday, President Trump stood beside Health and Human Services Secretary Robert F. Kennedy Jr. for what he called a "historic" announcement on autism.

See Full Page